There is increasing clinical evidence that phospholipid oxidation products (Ox-PL) play a role in atherosclerosis. This review focuses on the mechanisms by which Ox-PL interact with endothelial cells, monocyte/macrophages, platelets, smooth muscle cells, and HDL to promote atherogenesis. In the past few years major progress has been made in identifying these mechanisms. It has been recognized that Ox-PL promote phenotypic changes in these cell types that have long-term consequences for the vessel wall. Individual Ox-PL responsible for specific cellular effects have been identified. A model of the configuration of bioactive truncated Ox-PL within membranes has been developed that demonstrates that the oxidized fatty acid moiety protrudes into the aqueous phase, rendering it accessible for receptor recognition. Receptors and signaling pathways for individual Ox-PL species are now determined and receptor independent signaling pathways identified. The effects of Ox-PL are mediated both by gene regulation and transcription independent processes. It has now become apparent that Ox-PL affects multiple genes and pathways, some of which are proatherogenic and some are protective. However, at concentrations that are likely present in the vessel wall in atherosclerotic lesions, the effects promote atherogenesis. There have also been new insights on enzymes that metabolize Ox-PL and the significance of these enzymes for atherosclerosis. With the knowledge we now have of the regulation and effects of Ox-PL in different vascular cell types, it should be possible to design experiments to test the role of specific Ox-PL on the development of atherosclerosis. (Circ Res. 2012;111:778-799.) 
and rheumatoid arthritis. 3 Oxidized phospholipids are also present in vivo in lipoprotein(a), in membranes of apoptotic cells, and cells undergoing oxidative stress. 1 Evidence for the importance of these lipids in heart disease and atherosclerosis comes from several types of studies: 1) In a number of studies, the largest of which was the EPIC Norfolk study, levels of Ox-PL in plasma are associated with increased risk of coronary artery disease (CAD). 4 It is however important to recognize that these studies used E06 antibody, which recognizes only a subset of Ox-PL. Ox-PL levels in plasma were also shown to increase during regression. [5] [6] [7] In these papers they postulate that this increase represents a release from the vessel wall and may aid lesion regression. However, studies with statins have not yet shown a relationship between the Ox-PL increase in plasma by statins and the volume of atherosclerotic lesions in the coronary arteries. It will be important to resolve the issue of whether movement of lipids from the vessel wall is truly a measure of regression. 2) Studies of hyperlipidemic plasma from mice and humans suggest a role for phospholipid oxidation products in thrombosis. Hyperlipidemic animals had higher levels of Ox-PL in the plasma, and treatment with Ox-PL increased platelet activation. 8 Platelet activation was also increased when using plasma from human donors with the highest levels of Ox-PL. 8 3) Studies in mice also suggest a role for Ox-PL in atherosclerosis. Overexpression of one of the enzymes involved in formation of Ox-PL, myeloperoxidase (MPO), increases atherosclerosis, 9 and knockout of 12/15 lipoxygenase (12/15 LO), another enzyme shown to produce Ox-PL, decreases atherosclerosis. 10 Plasma levels of MPO and its products predict an increase in CAD risk in healthy humans. 9 4) D4F, a HDL mimetic peptide, strongly protects against atherosclerosis in mice, and a major function of D4F is binding to phospholipid and fatty acid oxidation products. 11 Although these studies are highly supportive of a role for Ox-PL in atherosclerosis, they are not definitive. It will be important to demonstrate that manipulation of the receptors, signaling pathways, and metabolism of Ox-PL affect atherosclerosis. Since 2 major reviews of Ox-PL were published in 2009 -2010, this review focuses on papers published in the past 3 years that address the role of Ox-PL in atherosclerosis.
Phospholipid Oxidation Products
There are a large number of phospholipid oxidation products that are formed from a variety of phospholipids containing polyunsaturated fatty acids. More than 30 different bioactive oxidation products have been identified that accumulate in lesions. Representative Ox-PL receiving the most study are shown in Figure 1 . Furthermore, the common and International Union of Pure and Applied Chemistry (IUPAC) names of the sn-2 position of these phospholipids, in addition references for synthesis/identification and characterization are given in Table 1 . Ox-PL contain saturated fatty acids of different lengths at the sn-1 position, either acyl or alky esters, and contain phosphatidylcholine (PC), phosphatidylserine, or phosphatidylethanolamine head groups. 1, 2 In vitro, Ox-PL have been produced by a variety of methods of oxidation, all of which yield active products. The majority of studies of these molecules have been done on oxidation products of phospholipids with arachidonate or linoleate in the sn-2 position. However, important studies have also examined effects of phospholipids containing docosahexaenoic acid. Some Ox-PL contain fragmentation products of arachidonate or linoleate whereas others contain derivatives of arachidonate and linoleate that have become oxygenated. The structure of the lipid at the sn-2 position plays a major role in receptor recognition of Ox-PL. In general, differences in the sn-1 fatty acid group of Ox-PL and have minor effects on action. 2 Alkyl and acyl containing phospholipids bind with different affinities to Ox-PL receptors. The head group can mediate a difference in activity, though not all effects of Ox-PL are sensitive to head group changes. One example is that EO6 recognizes PC-containing but not phosphatidylserine-or phosphatidylethanolamine-containing Ox-PL. 12 Another example of head group preference is the differences in ability of oxidized PC-containing phospholipids (Ox-PC) and oxidized phosphatidylserine-containing phospholipids to block the uptake of apoptotic cells by macrophages. 13, 14 Many Ox-PL are active electrophiles and can covalently bind to lysines, forming Schiff bases, or to cysteine or histidine, forming Michael Adducts (Figure 2 ). These interactions may result in covalent binding or reversible interactions. Some Ox-PL such as 1-palmitoyl-2-(5-hydroxy-8-oxooct-6-enoyl)-sn-glycero-3-phosphocholine, 1-palmitoyl-2-(4-hydroxy-7-oxohept-5-enoyl)-snglycero-3-phosphocholine, and isolevuglandin-PC can interact with proteins and form pyrrole groups (eg, 2 (wcarboxyethyl)pyrrole [CEP] ) which remain attached to the proteins ( Figure 2 ). 15, 16 Some of these covalently bound products act as ligands for receptor activation. The extent of covalent binding varies for different Ox-PL and is strongest for isolevuglandin-PC. Covalent binding can also activate cell surface proteins. 17 
Summary of Vascular Cell and HDL Effects of Oxidized Phospholipids
Ox-PL have both atherogenic effects on cells and effects that have been shown to reduce atherosclerosis or protect cells against apoptosis ( Table 2) , but the net effect of Ox-PL on vascular wall cells and on HDL function is proatherogenic. This review focuses on effects of Ox-PL on endothelial cells, smooth muscle cells (SMCs), platelets, and macrophages. Although lymphocytes are important regulators of atherosclerosis 18 we have not included lymphocytes in this review because there are only a few studies on Ox-PL regulation in lymphocytes. However, we have referred to the effects of antibodies to Ox-PL as inhibitors of atherosclerosis. The effects of these antibodies have recently been reviewed. 19 
Endothelial Cells
A number of papers over the past 12 years have documented the effects of Ox-PL on endothelial cells. 1, 2 Taken together these studies suggest that PC-containing Ox-PL (eg, oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine [Ox-PAPC]) is a strong regulator of endothelial cell function. More than 1000 genes are regulated by treatment of human aortic endothelial cells (HAEC) for 4 hours with 40 g/mL Ox-PAPC. 20,21 80% of these genes were also regulated by 1 Ox-PAPC component, 1-palmitoyl-2-(5,6-epoxyisoprostane Table 1 . PAF indicates platelet activating factor; HAz-PC, hexadecylazelaoyl PC; 13-HODE-PC, 1-palmitoyl-2-(13(S)-hydroxy-(9Z,11E)octadeca-9,11-dienoyl)-sn-glycero-3-phosphocholine.
E 2 )-sn-glycero-3-phosphocholine (PEIPC) (1-5 g/mL). 21 The major gene ontology categories regulated by Ox-PAPC include sterol synthesis, unfolded protein response (UPR), redox signaling, inflammation, angiogenesis, cell division, endocytosis, filament formation, ecto-protease regulation and thrombosis. Some of these genes can perform protective functions, whereas others are atherogenic. Most regulated genes were in the "protective" categories. Array analysis of endothelial cells from 150 different human donors showed considerable differences between individuals in gene regulation by Ox-PAPC. Longer treatment with Ox-PAPC was shown to induce angiogenesis 22 which leads to plaque instability. 23 Ox-PAPC and PEIPC also cause rapid effects on monolayer permeability, independent of mRNA synthesis. At low concentrations of lipid there was a protective effect on junctions whereas higher concentrations led to a decrease in the endothelial barrier. 24, 25 Overall, these studies suggest that at early times of Ox-PAPC treatment the endothelium is subject to oxidative stress, and that this induces pathways to protect against the stress, such as the UPR response, an increase in antioxidant genes and decreased DNA replication. However, at the same time these cells up-regulate genes involved in inflammation, procoagulant activity and angiogenesis and also decrease endothelial barrier function. Taken together these studies suggest that, over the long term, endothelial cells survive Ox-PAPC injury and become inflammatory and angiogenic, contributing to plaque instability. It will be important to compare gene regulation in vitro to that found in endothelial cells of human and mouse lesions. Ambient air pollution has been associated with increased cardiovascular morbidity and mortality, and Ox-PAPC was shown by microarray analysis to synergize with fine particles in air pollutants to activate proatherogenic pathways in endothelial cells. 26 
Macrophages
Another cell type where multiple effects of Ox-PL have been observed is macrophages. Early studies from the Witztum group demonstrated that uptake of oxidized LDL (Ox-LDL) led to foam cell formation, and they subsequently identified 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC) as 1 lipid responsible for foam cell formation. 27 The E06 antibody, which binds to a number of short chain Ox-PL, could block foam cell formation by macrophages. Podrez et al 28 demonstrated that at least 8 Ox-PL that contain fragmentation products of arachidonate and linoleate interacted with the cluster determinant 36 (CD36) receptor on macrophages, resulting in rapid Ox-LDL uptake and foam cell formation. These lipids were enriched in human atherosclerotic lesions. 29 Once monocytes enter lesions, they differentiate to macrophages and can produce cytokines. Ox-PAPC induces the production of macrophage cytokines. 30 Platelet activating factor (PAF) and PAF-like Ox-PL can also increase synthesis of monocyte chemotactic protein (MCP)-1 in several types of leukocytes. 31 Ox-PL also have effects on the initiation of apoptosis in macrophages 32 and the uptake of apoptotic cells by macrophages. 14, 33 Macrophage apoptosis has been shown to play an important role in atherosclerosis. There is evidence that if it occurs at early times, atherogenesis may be inhibited; whereas if apoptosis occurs after foam cell formation, it may increase the formation of the necrotic core and increase atherogenesis.
The differentiation of macrophages and dendritic cells has also been shown to be affected by Ox-PL. Kadl et al 34 described a novel macrophage phenotype (named Mox) that develops in response to treatment with Ox-PAPC. Treatment of macrophage subtype (M)0, M1 or M2 macrophage subtypes with Ox-PAPC resulted in the Mox phenotype. 34 These Mox cells exhibited a lower capacity for migration, phago- cytosis, and production of inflammatory stimuli. They were shown to contain high levels of antioxidant enzymes. These macrophages represent about 30% of cluster of differentitation 11b antigen/F480ϩ cells in mouse atherosclerotic lesions and may contribute to the buildup of macrophages in lesions.
Dendritic cells in apoE null mice have a diminished ability to promote T-cell responses. 35 Oxidized phospholipids were shown to dysregulate the differentiation of dendritic cells from monocytes in culture. 36, 37 Ox-PAPC addition to dendritic cell differentiation medium caused the production of dendritic cells that did not express CD1a, CD1b or CD1c; however other dendritic markers were still induced. Thus these Ox-PAPC-treated dendritic cells were not able to present lipid antigens and thus could not mount an antibody response to these antigens. These authors present evidence that Ox-PL inhibits the phosphorylation of Histone H3, which has previously been shown to regulate differentiation of dendritic cells by CD40 ligand. 36 Ox-PL also inhibited CD1 expression in dendritic cells treated with mycobacteria, 37 and CD1 was inhibited in lepromatous lesions which contain high levels of Ox-PL as seen with E06 staining.
SMCs
Ox-PAPC promotes phenotypic switching in SMCs, including suppression of contractile SMC differentiation marker genes. 38 POVPC and PEIPC, as well as Ox-PAPC, also increased expression of matrix protein type VIII collagen and fibronectin, which increases SMC migration. 39 POVPC changed the phosphorylation state of connexin 43, which stimulates SMC replication. 40 All of these effects were observed in vitro as well as in vivo and reflect a switch to an atherogenic phenotype. Ox-PAPC was also shown to be involved in SMC apoptosis. 41 In human lesions extensive SMC death is observed.
Platelets and Thrombosis
Thrombotic processes are also induced by Ox-PL. As discussed above, hyperlipidemic serum increases platelet reactivity. 8 Several individual Ox-PL, found in hyperlipidemic plasma and which can bind to CD36, were shown to sensitize platelets to adenosine diphosphate-induced aggregation. Another study demonstrated the importance of the PAF receptor in the regulation of platelet activation by alkyl Ox-PL. 42 Thus more than 1 receptor appears to contribute to the hyperaggregation of platelets in hypercholesterolemia. In addition, several groups have shown that platelets actually form 12S-hydroxyeicosatetraenoic acid (12-S-HETE)-containing oxidized phospholipids after exposure to thrombin, ionophore or collagen. 43 Furthermore, liposomes containing these phospholipids are able to enhance tissue factor-dependent coagulation.
In microarray studies, Ox-PAPC treatment of HAEC from 150 donors was shown to regulate the levels of major thrombogenic molecules. 21 Ox-PAPC significantly downregulated thrombomodulin expression by 40% while upregulating tissue factor and Serpin B2ϫ70%. Taken together, these platelet and thrombotic changes could play a major role in CAD.
Ox-PAPC Interactions With HDL
In addition to the proatherogenic effects of Ox-PL on cells, there is evidence that the binding of Ox-PL to HDL can decrease HDL anti-inflammatory and cholesterol transport functions. 44 HDL was shown to be a repository for lipid hydroperoxides. 45 Hydroxynonenal (HNE), an oxidized fatty acid, binds to apolipoprotein AI and regulates HDL's cholesterol transport and inflammatory functions. 44 Because most polyunsaturated fatty acids in living systems are complexed with phospholipids, it was important to examine the binding of Ox-PL to apolipoprotein AI. Using a biotinylated-sulfoxide analog of 1-palmitoyl-2linoleoyl-sn-glycero-3-phosphocholine, Szapacs et al demonstrated binding of several Ox-PL, derived from the biotinylated lipid, to apolipoprotein AI at important functional sites in the molecule. 46 These included sites involved in lecithin-cholesterol HAEC, human aortic endothelial cells; SMC, smooth muscle cells; HUVEC, human umbilical vein endothelium; IL, interleukin; MCP, monocyte chemotactic protein; VEGF, vascular endothelial growth factor; CS-1, connecting segment 1; KLF4, Krueppel-like factor 4; UPR, unfolded protein response; VEGFA, vascular endothelial growth factor A; HO-1, hemeoxygenase 1; MIP1, macrophage inhibitory protein 1; LTB4, leukotriene B4; RANTES, regulated upon activation, normal T-cell expressed and secreted; TF, tissue factor; TM, thrombomodulin; FN, fibronectin; VAV, VAV family of guanidine nucleotide exchange factors; NQO1, NAD(P)H dehydrogenase, quinone 1; GLCM, glutamine cysteine ligase.
acyl transferase (LCAT) binding and activation. It will be important to also determine the effects of covalent lipid binding on the anti-inflammatory effect of HDL. The importance of oxidized fatty acids and Ox-PL in regulating HDL function is also suggested by studies demonstrating that D4F, which binds fatty acid oxidation products whether free or esterified to phospholipids, protects against the proinflammatory effects of dysfunctional HDL. 11 Overall, Ox-PL can mediate proatherogenic changes of all the cell types examined and inhibits the protective functions of HDL.
Identifying the Receptors and Signaling Pathways Regulated by Ox-PL
In order to develop strategies for inhibiting the effects of oxidized phospholipids, it is important to identify the most active Ox-PL species and determine their mechanisms of action. There are a number of issues that need to be considered when analyzing effects of Ox-PL. Many studies have been performed using mixtures of oxidized lipids such as mildly oxidized LDL, Ox-PAPC and Ox-1-palmitoyl-2-linoleoyl-sn-glycero-3phosphocholine. Others have used pure molecular species of Ox-PL. Lipid mixtures have been useful in identifying major processes regulated by Ox-PL, and it is likely that Ox-PL are presented to cells as mixtures. However, in order to identify particular Ox-PL causing a given effect on cells, these lipids must be studied in isolation from other oxidized phospholipids. Another issue when testing lipid mixtures or individual lipids is how much lipid should be used. This is a difficult issue because, until recently, methods for determining absolute levels of these lipids in vivo were not sufficiently accurate or available. Although methods for measuring free Ox-PL have improved, it is important to recognize that many Ox-PL can covalently bind to proteins, and the levels of these bound lipids will not be measured by the lipid extraction method. In spite of these problems, several papers give levels that can guide studies of mechanism. In more recent studies the levels of individual Ox-PL in atherosclerotic lesions have been reported to be approximately 1 to 3 mol/L in human and mouse atherosclerotic vessels. 47 The values of Ox-PL in lesions may be consid-erably higher than these values because whole aortic arches were used in mice and carotid endarterectomy specimens in humans. A large fraction of these tissues are often not actively engaged in atherogenesis. In plasma, levels were approximately 10% of those in lesions. 47 In another study the combined values of Ox-PAPC, which bound to CD36 ranged from 5 to 51 mol/L in plasma. 8 In selecting the appropriate concentration of an individual lipid to use, one must consider that in lesions there may be a number of atherogenic Ox-PL that have similar functions. Therefore it may be necessary to use higher levels of individual phospholipids to obtain a maximal response. Also, when using mixtures of Ox-PL, such as Ox-PAPC, the concentration to be used will be higher than for individual active Ox-PL because some lipids in the mixture may have low activity.
Two other important issues, the time of treatment and cell type used, are critical considerations in deciding on an experimental design. Although this is true for all cell treatments in general, it is especially true for Ox-PL since they may have opposite effects at different times after treatment and very different effects in different cell types. For example after 4 hours of treatment of endothelial cells with Ox-PL replication is inhibited. However, after 24 hours angiogenesis is stimulated. 22 The number of genes regulated by Ox-PAPC after a 4 hour treatment of human aortic endothelial cells is much higher than that seen in human macrophages treated for the same time with the same concentration ( Figure 3 ). Whole gene ontology categories regulated by Ox-PL in endothelial cells are not regulated in macrophages.
Ox-PL Primary Interactions: Receptor and Nonreceptor Mechanisms
A number of studies have addressed the question of the primary event regulating the interaction of Ox-PL with cells. Ox-PL also interact with soluble receptors and this area has been recently reviewed. 19 Cell receptors binding specific Ox-PL or groups of Ox-PL have been identified (CD36, 13, 28 scavenger receptor B1 (SRB1), 48 Toll-like receptor (TLR)2, 32,49 TLR4, 50 -52 E-type prostaglandin receptor (EP2) 53 ). The PAF receptor, PAF binding, and the internalization receptor transmembrane protein 30A (TMEM30a) have also been shown to play a primary role in the action of Ox-PL. 54, 55 The relative roles of these receptors in the activation of specific pathways may differ. In addition, recent information suggests that nonreceptor-mediated events may be causal in the initial response to selected Ox-PL. These include changes to the lipid composition and fluidity of the plasma membrane subsequent to incorporation of Ox-PL 56 -58 and covalent interaction of Ox-PL with cell surface proteins. 17, 49 Identification of the primary event in Ox-PL regulation of cells is an important therapeutic goal.
Configuration of the Ox-PL Ligand
An important consideration in determining the mechanism by which Ox-PL interact with their receptors is the configuration of the Ox-PL ligand. Cells likely see phospholipid oxidation products in membranes, for example the membranes of apoptotic cells or membrane containing structures like LDL. Studies from the Hazen and Salomon labs 59 have produced a model of the configuration of specific phospholipid oxidation products in membranes, referred to as the Lipid Whisker model. For these studies, they used vesicles of unoxidized PL containing 5 to 20mol% of specific Ox-PL. They used NMR, nuclear overhauser effect (NOE) to define the configuration of the specific Ox-PL in membranes. They showed that the addition of polar oxygen atoms to fragmentation products of arachidonate and linoleate reorients the sn-2 acyl chain. This increases the hydrophilicity of this group causing it to protrude into the aqueous phase where the head group is located. This contrasts with the sn-2 chain of the unoxidized parent phospholipid (PAPC), which is buried in the lipid bilayer. The fact that the head group and sn-2 fatty acid oxidation products are both in the aqueous phase may account for the fact that, in some situations, both are important for recognition. The presence of the fragmentation product in the aqueous phase, rather than buried in the lipid bilayer (as seen with PAPC or 13-HODE-PC), enables contact between the receptor and the sn-2 position of the ligand (Figure 4 ). This same sn-2 configuration was seen with PC-and phosphatidylethanolamine-containing Ox-PL. The configuration of Ox-PL containing alkyl fatty acid at the sn-1 position has not been determined but the protrusion of the sn-2 group into the aqueous phase may also be relevant for these lipids.
Cell Surface Receptor Activation by Ox-PL
There are multiple receptors regulating Ox-PAPC action. Some of these receptors appear to act alone whereas others require the presence of receptor complexes. Most of the initial studies were done in vitro but the importance of some of these receptors in atherosclerosis has been confirmed in vivo in mice.
CD36
The most well studied receptor for Ox-PL is CD36. The Ox-PL involved in the binding to CD36 contains fragmentation products of arachidonate and linoleate that contain a terminal acid or aldehyde. This group of CD36-binding phospholipids is referred to as a group of Ox-PC binding to CD36 (Ox-PC CD36 ). 28 Using model phospholipids Gao et al 60 showed that a carboxylate tail at the terminal of the sn-2 position is most important for binding and that ␣,␤ unsaturation also plays a role as did chain length and the charge at the sn-3 position. 60 Several lysines in CD36 were shown to be required for the interaction with Ox-PC CD36 . CD36 also binds to oxidation products of docosahexaenoic acid that contains a terminal acid or aldehyde. 61 Knockout of CD36 in mice modestly decreased atherosclerosis. 62
SRB1
Several of the Ox-PC CD36 lipids were also shown to bind to SRB1. In general, the binding to SRB1 showed comparable binding requirements to CD36 but SRB1 had a lower binding affinity for Ox-PL. Furthermore SRB1 requires longer chains at the sn-2 position for optimal binding. 60 The Ox-PC CD36 binding site on SRB1 was identified and shown to also be a binding site for HDL. For this reason, treatment of hepatocytes with Ox-PC CD36 blocked SRB1-mediated uptake of cholesteryl esters. 60
TLR2 and TLR4
There is evidence that TLR2 30, 32, 49 and TLR4 50 -52 may act as Ox-PL receptors. TLR2 was involved in the initiation of angiogenesis by the interaction of CEP-containing proteins with TLR2. 49 CEP-bound proteins and CEP itself were able to interact with and activate TLR2. In a separate study a role for TLR2 in the macrophage inflammatory response to Ox-PAPC was demonstrated. 30 Treatment of mouse macrophages with Ox-PAPC caused an increase in expression of the inflammatory cytokines, and this was not observed in TLR2 null mice. This effect was stronger for Ox-PAPC lipids (like PEIPC) containing reducible groups in the sn-2 position and was inhibited by reduction of the lipid with sodium borohydride. Knockout of TLR2 in mice was shown to cause a general decrease in early atherosclerosis. However, the major effect was not mediated by bone marrow derived cells. 63 It is possible that both roles for bone marrow-derived and nonbone marrow-derived effects are important at different stages of atherosclerosis. TLR4 has a role in Ox-PAPC activation of Hela cells 52 and macrophages. 50, 51 The binding of Ox-LDL to CD36 mediated increases in chemokines GRO1, macrophage inhibitor protein 2, and regulated on activation, normal T-cell expressed, and secrete in macrophages. This increase was inhibited when TLR4 or TLR6 were absent from the macrophages. 51 These authors determined that a complex of CD36 with TLR4 and TLR6 was necessary for this activation and that tyrosine protein kinase Lyn activation in the complex was also required. The role of Ox-PL in the Ox-LDL activation was not determined. Dominant negative and antisense oligonucleotides to TLR4 blocked the effect of Ox-PAPC and POVPC on activation of the interleukin (IL)-8 promoter in Hela cells. 52 Studies of the role of TLR4 have, however, been inconsistent in human aortic endothelial cells and may depend on the presence of coreceptors. Knockout of TLR4 in apoE null mice fed a chow diet caused a decrease in early atherosclerosis without a change in cholesterol levels. 64 Some human studies suggest that a TLR4 polymorphism may be associated with atherosclerosis. It may be important in human studies to examine a combined risk of TLR4 and TLR6 polymorphisms.
EP2
The receptors described above all recognize multiple Ox-PL. A more specific receptor that has been identified is EP2, a prostaglandin and isoprostane receptor. The role of this receptor in Ox-PAPC action was examined because PEIPC contains an E 2 isoprostane group. Ox-PAPC and PEIPC were shown to bind to EP2 and this interaction regulates monocyte binding to endothelial cells. 53 Prostaglandin E 2 has been shown to have an effect on monocyte binding similar to PEIPC. However, EP2 was subsequently shown to regulate only a small subset of the PEIPC effects on HAEC. These studies have been done only in vitro and a role for EP2 should be examined in mouse models.
PAF Receptor
The most extensively studied Ox-PL are acyl phospholipids that contain an ester-bonded fatty acid at the sn-1 position of the molecule. However, there are a comparable number of alkyl oxidized PL with ether bonds at the sn-1 position. Though the levels of these alkyl Ox-PL are much lower, they are highly potent activators of leukocyte interaction with endothelial cells and regulators of platelet function. The effects of these lipids have been shown to be regulated by the PAF receptor. 54 There is also evidence that acyl Ox-PL may bind to the PAF receptor because the effects of Ox-PAPC and POVPC and several other acyl phospholipids can be inhibited by PAF receptor antagonists. 54 Furthermore, WEB2086, a PAF receptor antagonist, decreases atherosclerosis in mice. 65 The fact that a PAF receptor antagonist inhibits the development of atherosclerosis suggests that alkyl-linked Ox-PL as well as acyl-linked Ox-PL are important in the early stages of atherosclerosis.
TMEM30a
Several studies have suggested that phospholipid oxidation products can cross the plasma membrane. Studies using tagged Ox-PAPC showed its presence in several cell membrane compartments. 66, 67 TMEM30a is a receptor that transports PC-and phosphatidylethanolamine-containing phospholipids into cells. It is found in the plasma membrane and in membranes of several cell organelles. In vivo, PAF-AH (platelet activating factor acetyl hydrolase) was shown to play only a small role in the clearance of PAF and PAF-like alkyl Ox-PL from the blood, with transport into cells being more important in clearance. PAF and PAF-like lipids were mainly taken up into cells by TMEM30a. 68 Knockdown of TMEM30a reduced the apoptotic effect of an endogenous alkyl phospholipid oxidation product. It remains to be determined if acyl Ox-PL can also be taken up by this receptor or by an alternate receptor. It would be important to confirm a role for this receptor in atherosclerosis in mice.
Non-Receptor Mechanism

Covalent Binding to Cell Surface Proteins
The importance of covalent or strong interactions with cell surface proteins as regulators of Ox-PL action has received increasing attention over the past several years. The study discussed above concerning the interaction of CEP with TLR2 provides evidence that such interactions occur in vivo and are important in the action of Ox-PL. 49 In a number of diseases, including atherosclerosis, pyrroles have been shown to accumulate and may serve as disease markers. 16 The binding of Ox-PAPE-N biotin (oxidized 1-palmitoyl-2arachidonoyl-sn-glycero-3-phosphatidyl-(N-biotinylethanolamine), which has similar activities to Ox-PAPC to approximately 20 proteins in endothelial cells was reported several years ago. 66 Recent studies have shown that Ox-PAPC can covalently interact with and activate 2 specific metalloproteinases, a dysintegrin and metalloproteinase 10 (ADAM10) and a dysintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4), which are present on the cell surface. 17 This activation results in an increase in the transcription of proinflammatory genes including IL-8 and MCP-1. It would be important to look for covalent binding to ADAM10 and ADAMTS4 in vivo. A recent review has focused on protein modification by aldehydophospholipids and its functional consequences. 69
Cholesterol Depletion and Membrane Stiffening
Several groups have reported changes in membrane characteristics when Ox-PL, Ox-LDL or oxysterols are incorporated into the membranes. 56, 57 A major finding in pig aortic endothelial cells is an increase in membrane disorder, increase in cell stiffness and a decrease in the cholesterol content of caveolar and noncaveolar lipid rafts after exposure of the cells to Ox-LDL. 56 Although it is counter intuitive, 3 pieces of evidence suggest that cholesterol depletion has occurred in lipid rafts of these endothelial cells after treatment with Ox-LDL. First, the distribution of raft markers is changed. Second, Ox-LDL exposure causes physical changes to the membrane consistent with cholesterol loss. Third, the effects of Ox-LDL can be mimicked by cholesterol depletion with methyl-␤-cyclodextrin. 56 One possible cause of this effect on membrane structure is an insertion of oxysterols into the membrane. 56 Another mechanism may relate to the observation that incorporation of Ox-PL into lipid monolayers results in monolayer expansion and subsequent loss of Ox-PL from the monolayer, thereby changing monolayer characteristics. 57 In HAEC, Ox-PAPC causes caveolar cholesterol depletion and an increase in sterol regulatory element binding protein (SREBP) activation. 58 Exposing HAEC to cholesterol reversed the effect of Ox-PAPC on IL-8 induction. There is also in vivo evidence for a decrease in membrane cholesterol in atherogenic conditions. First, in apoE null mice fed a high cholesterol diet, there is a decrease in endothelial caveolae on the cell surface. 70 Second, SREBP is activated in areas of human atherosclerotic lesions where inflammatory cells are present. 58 Taken together, these studies suggest that changes in cholesterol and in the fluidity of membranes where signaling molecules are present may lead to an increase in gene expression and other changes to endothelial cell function in response to Ox-PL. A study in human lesions examining the endothelial expression of several genes controlling cholesterol levels would clarify the role of cholesterol in regulating different stages of the disease.
Signaling
A number of signaling pathways have been shown to be activated by Ox-PL. Changes in second messenger occur as early as 2 minutes after treatment, and secondary signals may be sustained for many days. For some signaling events the entire process from the receptor to the downstream function has been identified. In other cases only part of the pathway has been determined. Because various parts of the pathway are potential drug targets, we have presented both complete and incomplete pathways. Some signaling studies have been done with Ox-LDL and may or may not apply to effects of oxidized phospholipids because Ox-LDL contains both sterol and phospholipid oxidation products. Therefore, we have only included Ox-LDL studies where the receptor or signaling pathway is also known to be activated by oxidized phospholipids.
Macrophages
Foam Cell Formation CD36 is recognized to play a major role in foam cell formation. Originally CD36 was thought to be a scavenger receptor and not a signaling receptor. It is now recognized that CD36 activation by Ox-PC CD36 lipids has important signaling functions that affect both foam cell formation and platelet activation. The ability of Ox-PC CD36 to stimulate foam cell formation was shown to relate to a stimulation of endosomal vesicle trafficking. 71 This pathway involves the rapid activation of tyrosine protein kinase Lyn followed by the activation of VAV family of guanine nucleotide exchange factor (VAV) proteins that are known to be involved in receptor ligand endocytosis in other cell types. These VAV proteins constitutively interact with dynamin2. On activation of CD36, dynamin is phosphorylated and the dynamin/VAV complex moves from the plasma membrane to the perinuclear area. There is also an increase in Ca 2ϩ entry into the cells that increases endocytosis and provides positive feedback in the process.
Ox-PC CD36 3CD363tyrosine protein kinase Lyn/ Fyn*3VAV*3PLC␥*3d ynamin-P 3 calcium flux3 uptake of Ox-LDL A secondary pathway regulated by C-Jun N-terminal kinase (JNK) phosphorylation also appears to be important because JNK null mice have decreased foam cell formation in vitro and in vivo. It will now be important to examine the importance of this pathway in a mouse model of atherosclerosis and determine if this pathway is activated in human lesions.
Increase in Cytokine Expression
TLR2 was found to be involved in the proinflammatory Ox-PAPC response in macrophages, including induction of cyclooxygenase 2 (COX2), IL-1␤, macrophage inhibitor protein 2 and keratinocyte chemoattractant (KC). 30 The response to high molecular weight species of Ox-PAPC, such as PEIPC, was blunted in bone marrow derived macrophage from TLR2 Ϫ/Ϫ mice as compared to wild type mice. P38 and JNK are phosphorylated in wild type but not TLR2 knockout macrophages, suggesting that these proteins are involved in the proinflammatory response. The induction of the proinflammatory genes did not involve activation of NFB (nuclear factor -light-chain-enhancer of activated B cells). Studies cited above 63 however suggest that macrophage TLR2 is not involved in atherosclerosis. However, there may be compensatory mechanisms in the TLR2 knockout mice. An examination of the pathways identified by Kadl et al in macrophages from TLR2 null and WT mice might help to resolve the question of whether macrophage TLR2 is an important regulator of atherosclerosis.
Ox-PL activation of the PAF receptor with alkyl Ox-PL was shown to increase chemokine synthesis in both monocyte and neutrophils. Treatment with Ox-PL increased the levels of macrophage inhibitor protein-1, and -2 (MIP1, 2) and MCP-1. Levels of leukotriene B4, another monocyte chemotactic factor, were also increased. 31, 72 The induction of MCP-1 synthesis was shown to require both NFB activation and Ca 2ϩ /calcineurin signaling pathways. A dose response study comparing the effects of alkyl and acyl Ox-PL on chemokine synthesis by macrophages would suggest the relative roles of the PAF and TLR2 receptors.
One of the most important chemotactic factors for monocytes in atherosclerosis is MCP-1. Mitogen activated protein kinase phosphatase 1 (MKP1) is highly and rapidly induced by Ox-PAPC and plays an important role in Ox-PAPC induction of MCP-1 in endothelial cells and macrophages. 73 The exact mechanism controlling this regulation is not known. However, knockout of mitogen activated protein kinase phosphatase 1 in apoE null mice fed a chow diet for 24 weeks caused a major reduction in levels of MCP-1 in plasma and also a decrease in the size of atherosclerotic lesions. 73 A microarray study on the effect of mitogen activated protein kinase phosphatase 1 might aid in the understanding of the regulatory effect on this molecule.
Apoptosis
Ox-PL stimulates macrophage apoptosis and play an important role in the uptake of apoptotic cells by macrophages. CD36 and TLR2 play important roles in the ability of Ox-PAPC to facilitate apoptosis in connection with the UPR. 32 In cells with either CD36 or TLR2 knockout, the effect of Ox-PAPC on apoptosis was strongly inhibited. A TLR2/TLR6 heterodimer was necessary for this response. Ox-PAPC could be delivered either as free molecules or in combination with lipoprotein(a), which carries Ox-PAPC in plasma. Ox-PAPC was not the only lipid that accelerated apoptosis. These authors observed that reactive oxygen species (ROS) were increased in Ox-PAPC-treated cells. Activation of NADPH oxidase 2 (NOX2) was necessary for ROS formation and the apoptotic response. The response did not develop in cells from NOX2 null animals. ERK/MAPK (extracellularsignal-regulated kinases/mitogen activated protein kinase) activation was necessary for Ox-PAPC-induced increases in ROS and apoptosis.
Ox-PAPC3CD36/TLR23ERK/MAPK*3NOX2*ϩ UPR3apoptosis
Macrophage apoptosis in advanced lesions of TLR2/TLR4 deficient mice was decreased. The relevance of this pathway in human lesions should be examined by staining human lesions for NOX2 and ERK activation in apoptotic macrophages. TLR4 was mainly responsible for apoptosis of macrophages undergoing efferocytosis because of Ox-PAPC treatment. 74 In HL-60 cells (a premyelocytic cell line) treated with hexadecylazelaoyl PC (HAz-PC) (an alkyl phospholipid as opposed to the acyl phospholipids used for the previous study) apoptotic death was shown to be increased by affecting mitochondrial integrity. 75 This effect depended on uptake by TMEM30a. It will be important to determine whether TMEM30a is expressed in human macrophages undergoing apoptosis.
The uptake of apoptotic cells by macrophages has also been shown to be regulated by Ox-PL. Several groups have shown that during apoptosis macrophages produce Ox-PL. 14, 33, 76 This Ox-PL is present on the surface of the apoptotic cells and contributes to their uptake by macrophages. Phosphatidylserine-containing Ox-PL are more active than PC-containing phospholipids, however both are reactive. CD36 is strongly involved in the binding and uptake of apoptotic cells expressing oxidized phosphatidylserinecontaining phospholipids/PC CD36 . 13, 14 The uptake of apoptotic cells by CD36 has the potential to be antiatherogenic, whereas the uptake of lipid into foam cells is proatherogenic. The combination of these 2 functions may explain why CD36 knockout does not have a more robust effect in decreasing atherosclerosis. It would be interesting to use a CD36 inhibitory peptide to test effects of the receptor at different stages of atherosclerosis.
Platelet Activation and Thrombosis
Both the CD36 and PAF receptor were shown to play a role in platelet hypersensitivity to agents causing platelet aggregation. CD36 interaction with Ox-PC CD36 or Ox-LDL was shown to be involved in the hypersensitivity of hyperlipidemia. 8 The signaling pathway by which platelets are activated by Ox-LDL interaction with CD36 has many similarities to the regulation of foam cell formation by Ox-LDL. 77 CD36 engagement of Ox-LDL increased the activity of Fyn as shown by Fyn phosphorylation. This led to interaction of Fyn with VAV1 and phosphorylation of VAV1. Mice with deletion of VAV1 and VAV3 did not show platelet hypersensitivity. The exact mechanism by which VAV proteins affect platelets has not been identified. Previous studies have also shown that JNK activity is necessary for platelet hypersensitivity. Effects of a platelet specific knockout of VAV1 would clarify the issue of the direct involvement of platelet VAV in hypersensitivity.
The PAF receptor also contributes to early stages of platelet hypersensitivity. There is evidence that platelets can be activated by ether-containing oxidized phospholipids, one of which is HAz-PC. 42 Treatment of platelets with HAz-PC leads to a priming of platelet activation to a subthreshold level of thrombin, collagen and adenosine diphosphate. This leads to surface expression of P-selectin and an increase in calcium flux, which leads to platelet aggregation. Low levels of HAz-PC (10 Ϫ7 M) could induce this response, which was abolished at higher concentration. The effects of HAz-PC were reversed by PAF receptor antagonist WEB2086. A number of ether lipid oxidation products were effective and the effect did not correspond to chain length. The authors of this study speculate that, as more ligands binding CD36 accumulate in the vessel wall, CD36 becomes the dominant receptor mediating hypersensitivity.
Transcription of at least 3 proteins important in thrombosis is regulated by Ox-PAPC. Thrombomodulin down-regulation was shown to be regulated by a decrease in transcription mediated by decreased binding of retinoic acid receptor, retinoid X receptor, specificity proteins (Sp)1 and Sp3 to elements in the thrombomodulin promoter. 78 This decrease in binding was mostly due to decreased levels of these transcription factors in the nucleus. Ox-PAPC also strongly increases the levels of tissue factor mRNA. 79 This occurs by activation of PKC, which then activates ERK within 10 minutes of Ox-PAPC treatment. ERK was shown to activate the transcription factor EGR1, which then binds to the TF promoter. NGFI-A binding protein 2 (NAB2) overexpression, which inhibits EGR1 activation, inhibited the effect of Ox-PAPC on tissue factor mRNA. 1-palmitoyl-2-glutaryl-sn-glycero-3phosphocholine but not POVPC mimicked this effect. Vascular endothelial growth factor receptor (VEGFR2) activation by Ox-PAPC also mediates ERK phosphorylation. Furthermore, siRNA to VEGFR2 inhibited the induction of tissue factor by Ox-PAPC. 80 This suggests that VEGFR2 is the receptor mediating the pathway involved in EGR1 (early grown factor response protein 1) regulation of tissue factor.
Ox-PAPC3VEGFR2*3PKC3ERK-P 3EGR13
Tissue Factor
A second pathway of Ox-PAPC regulation of tissue factor involved Ox-PAPC activation of calcium entry into the cells, which then leads to nuclear factor of activated T cells (NFAT) translocation and binding of NFAT to the TF promoter. 79 Cyclosporin, which inhibits NFAT binding, decreased the effect of Ox-PAPC.
Ox-PAPC3Increased Calcium3NFATcyt3
NFATnuc3Tissue factor
Immunohistochemical staining of human lesions for the activation of these pathways would provide evidence for their potential role in human atherosclerosis.
Ox-PL containing a terminal 9 carbon aldehyde or carboxylic acid, but not those containing a 5 carbon aldehyde or those derived from Ox-PAPC, inhibit the activity of isolated tissue factor protein inhibitor, which inhibits the activity of tissue factor. 81 The mechanism inhibiting the activity was direct binding to the active tissue factor protein inhibitor domains. Thus, procoagulant activity is promoted by Ox-PL regulation of multiple cell-associated proteins in the coagulation pathway.
Endothelial Cells
A large number of endothelial cell functions are regulated by a 4 hour treatment of HAEC with Ox-PAPC. Analysis of HAEC microarrays from 150 donors demonstrated a significant regulation of more than 1000 genes with at least 600 regulated in each individual donor. These genes can be divided into 11 major categories of endothelial cell function. 21 It is clear that multiple pathways are involved in Ox-PAPC regulation of different groups of genes. In addition, Ox-PAPC affects important endothelial functions independent of transcription. Ox-PAPC rapidly activates monocyte binding to the endothelial cells and has a rapid effect on endothelial barrier properties independent of gene regulation. There is also regulation of endothelial function by pyrroles formed by Ox-PL. Thus, the endothelium is a major target of Ox-PL.
Transcription Independent Regulation
Monocyte Binding. Two major monocyte binding molecules on EC have been identified: vascular cell adhesion molecule-1 (VCAM-1) and the connecting segment 1 (CS-1) region of fibronectin, both of which bind monocyte integrin ␣ 4 ␤ 1 . VCAM-1 binding plays an important role in binding of monocytes to EC in mouse and rabbit atherosclerosis. However, VCAM-1 does not appear to play a major role in monocyte entry in large vessel endothelial cells of human lesions, although it is increased in small vessels of the adventitia in human lesions. 82 In mice, a CS-1 blocking antibody inhibits monocyte endothelial interactions by approximately 30%, whereas a blocking antibody to VCAM-1 inhibits binding by 70%. 83 The effect of Ox-PAPC on EC/monocyte interactions in HAEC involves increased deposition of an alternate splice form of fibronectin, which includes the CS-1 peptide. 84 Interaction of Ox-PAPC and PEIPC with the EP2 receptor on endothelial cells has been shown to regulate monocyte binding to HAEC. This interaction causes an increase in cyclic adenosine mono-phosphate, which increases R-Ras activation in part by first increasing and then strongly inhibiting H-Ras activation. The activation of R-Ras leads to activation of phosphoinositide 3 kinase (PI3K) which leads to activation of ␣ 5 ␤ 1 integrin. Activation of this integrin on the EC causes the deposition of the CS-1 peptide on the cell surface. The CS-1 deposits in patches in the areas of the cell where monocyte binding is observed.
PEIPC3EP2*3 protein kinase A (PKA)3R-Ras*, H-Ras3PI3K*3␣5␤1*3CS-1/Fn
Staining of carotid endarterectomy samples confirmed the presence of CS-1 on large vessel endothelium in areas of monocyte entry and a lack of an increase in VCAM-1 in these areas.
Monolayer Barrier Regulation. The monolayer barrier (involving EC/EC interaction) is regulated by adherens and tight junctions. Low concentrations of Ox-PAPC (5-20 g/mL) increased the EC monolayer barrier function whereas higher concentrations (25-100 g/mL) reversibly decreased barrier function. 24, 25 PEIPC (but not POVPC or 1-palmitoyl-2glutaryl-sn-glycero-3-phosphocholine) was able to mimic the Ox-PAPC effect to increase barrier function (JB, KBunpublished data); whereas POVPC and 1-palmitoyl-2glutaryl-sn-glycero-3-phosphocholine exclusively decreased barrier function. 2 Enhancement of barrier function involved activation of Rac1 and Cdc42, which then caused peripheral redistribution of focal adhesions, increased association of adherens junction complex containing VE-cadherin, ␣/␤/␥ catenin, and stimulated paxillin -␤-catenin interactions. 25 Low-dose Ox-PAPC, via activation of Rap-1, enhances interactions between adherens junctions and tight junction proteins. 85 These Ox-PAPC-induced associations were mediated by the Rap1-effector afadin, which promotes interactions between adherens junction protein p120-catenin and tight junction protein zona occludens 1. 85 Low concentrations of Ox-PAPC also induced Rac1-and p120-catenin-dependent peripheral accumulation and activation of Rho negative regulator, p190RhoGAP, which prevented endothelial monolayers from thrombin-induced barrier compromise via inhibition of Rho activity 24, 86 (Figure 5A ). Thus the increase in barrier function seen with low-dose Ox-PAPC can be attributed to changes in several GTPase proteins including Rac-1, Cdc42, and Rap-1.
Decreased barrier function in response to high-dose Ox-PAPC also involves changes to both adherens and tight junctions. At early times after treatment with high-dose Ox-PAPC, VE-cadherin, a key protein in maintaining barrier function, becomes highly phosphorylated in response to Src tyrosine kinase activation. 25 ROS also contribute to this phosphorylation. VE-cadherin hyperphosphorylation leads to a dissociation of VE-cadherin interactions with ␤-catenin and paxillin, VE-cadherin disappearance from cell-cell contacts and internalization. 25 These early changes could be reversed by ROS inhibitors. At later times, after high-dose treatment with Ox-PAPC, there was also an increase in Rho activation, which is known to decrease barrier function. Rho activation increases myosin light chain phosphorylation by inhibiting myosin phosphatase activity 24 and induces F-actin rearrangement from the cell periphery to stress fibers. These events trigger actomyosin contraction and a formation of gaps between the cells. Although high Ox-PAPC doses did not cause immediate Rho activation, increased Rho activity was observed after 30 minutes of high Ox-PAPC treatment, via VEGFR2 activation. 24 Activation of Rho signaling by vascu-lar endothelial growth factor (VEGF) has previously been shown to cause breakdown of endothelial monolayer permeability. 87 In addition to the weakening of adherens junctions, high-dose Ox-PAPC led to breakdown of tight junctions and decreased occludin expression at mRNA and protein levels. High-dose Ox-PAPC also increased occludin phosphorylation, which is known to decrease tight junction interactions. 88 These changes in occludin could be reversed by inhibiting the formation of ROS induced by high-dose Ox-PAPC ( Figure  5B) . A phospho-proteomic study has identified a large number of filament associated proteins phosphorylated in response to high-dose Ox-PAPC. 89 These effects of high-and low-dose Ox-PAPC on endothelial barrier function have been reported in the cultures of pulmonary and aortic EC, 24, 25 as well as in in vivo models of lung barrier dysfunction. 50, 90 These data strongly suggest that the pathways described here may contribute to atherosclerotic changes in vascular endothelial barrier function and accumulation of lipoproteins. It will be important to examine the presence of these pathways in early human lesions and to correlate this with staining for oxidized lipids.
Transcription Dependent Regulation
Regulation of Antioxidant Enzymes by Ox-PAPC. Treatment of endothelial cells with Ox-PAPC rapidly leads to induction of a large number of genes protecting against ROS, including hemeoxygenase I (HO-1), genes regulating glutathione metabolism and thioredoxins. 21 NRF2 (nuclear factor erythroid derived like 2) activation appears to play a major role in the Ox-PAPC regulation of a number of these genes and knockdown of NRF2 strongly decreases the effect of Ox-PAPC on these genes. 21, 91 The mechanism of NRF2 activation by Ox-PAPC is not certain but there is evidence that lipid electrophiles, like 15-deoxy-⌬12,14 -prostaglandin J 2 , can directly modify Keap1 leading to NRF2 activation. 92 A number of Ox-PL contain electrophilic groups and have the potential to modify Keap1. Another mechanism of NRF2 activation involves casein kinase 2. 93 Once activated NRF2 then binds to the antioxidant response element in the promoter region of the target genes, increasing transcription. For hemeoxygenase 1 (HO-1) , the effect of NRF2 knockdown is variable from 30% to 70% decrease. Several pathways of HO-1 regulation have been described. In HAEC a major role for the plasma membrane electron transport (PMET) system in HO-1 induction by Ox-PAPC was described. 94 This system is involved in moving electrons into and out of cells. Major proteins in the PMET complex are eNOX1 (ecto NADPH oxidase 1) and NAD(P)H dehydrogenase, quinone 1. With Ox-PAPC treatment the PMET system is activated and there is a transfer of electrons from an intracellular source (eg, NADPH) to an outside extracellular acceptor such as oxygen. This electron loss from the cells decreases the overall levels of NADPH in the cell, leading to an increase in ROS, activation of NRF2, and an increase in HO-1. Knockdown of a PMET protein, eNOX1, inhibited Ox-PAPC activation of NRF2 and HO-1 gene expression.
Ox-PAPC3PMET (e in 3e out )3NADPH23ROS3 NRF2*3HO-1
Another pathway of HO-1 activation by Ox-PAPC involved activation of CREB downstream of protein kinases A and C, P38 and ERK. 95 There was binding of CREB to an antioxidant response element in the HO-1 promoter. Thus, induction of HO-1 and other redox proteins by Ox-PAPC is likely regulated by multiple pathways, and different pathways may be important in different cell types. Several studies have shown that the signal transduction pathway upregulating antioxidant genes is distinct from those regulating inflammatory or procoagulant molecules. 1 Overexpression of several of these antioxidant genes decreases atherosclerosis in mice. Thus selective activation of the antioxidant pathways might provide a protective strategy in atherosclerosis.
UPR.
A prominent response to Ox-PAPC in HAEC is the activation of the UPR response. 20, 21 The UPR response has also been shown to be activated in both endothelial cells and macrophages of atherosclerotic lesions. 20 In endothelial cells all 3 arms of the UPR are activated by a 4 hour treatment of HAEC with Ox-PAPC. 96 The mRNA levels of activating transcription factor (ATF)-3 and ATF4 are increased as early as 1 hour after treatment. The UPR response, whereas protective at low levels can, at higher levels, lead to an increased inflammatory response and cell death, accelerating atherosclerosis. The mechanism of UPR activation by Ox-PAPC and HNE in endothelial cells has been the subject of several studies but a consensus has not yet emerged. In particular, the role of redox regulation of UPR is still unresolved. In human umbilical vein endothelial cells the Ox-PAPC-dependent increase in ATF4 was dependent on NRF2 binding to an antioxidant response element in the ATF4 promoter. 22 However, in HAEC the ability of Ox-PAPC to induce transcription of ATF4 was not affected by inhibiting NADPH oxidase 4 (NOX4), the major generator of ROS in response to Ox-PAPC. 97 HNE induction of UPR also involves depletion of glutathione. However, glutathione depletion did not cause UPR activation, measured as X-box binding protein 1 activation. 98 These authors suggested that direct binding of HNE to UPR proteins was likely responsible. One candidate for Ox-PAPC regulation of UPR came from studies of 150 endothelial donors, examining both untreated and treated HAEC. 99 These studies revealed a genetic hotspot controlling the transcription of 7 UPRassociated genes in treated cells and 33 genes involved directly or indirectly in the UPR response in untreated cells. The nearest gene to this hot spot was USP16 (ubiquitin specific peptidase 16). Knockdown of USP16 blocked the increase in these genes. Though previously unrecognized as a UPR regulator, this gene may be an important contributor to the UPR response in human patients. More studies will be necessary to resolve the important question of the mechanism of UPR regulation by Ox-PL. Sterol Regulation. As described above Ox-PL induce lipid raft cholesterol depletion and SREBP activation. 56, 58 This effect is not observed until approximately 1 hour after treatment but is sustained for at least 18 hours, and it likely plays a role in long term IL-8 induction. There is evidence that cholesterol depletion is mediated by ROS formation, both in response to VEGFR2 activation 80 and in response to uncoupling of endothelial nitric oxide synthase that occurs on endothelial nitric oxide synthase release from caveolae. 100 The endothelial nitric oxide synthase uncoupling is a feedforward mechanism that likely results in sustained SREBP activation. Studies on Ox-LDL suggest that cholesterol depletion can also result directly from incorporation of oxysterols into membranes. 56 Using other cell types and inducers, it was observed that activation of the UPR caused activation of SREBP. 101 However, in HAEC, inhibition of several branches of the UPR did not affect the Ox-PAPC-induced increase in LDLR or the decrease in ABCA1. 96 It will be important to determine the stages at which cholesterol depletion plays a role in altered endothelial function in atherosclerosis and whether at some stages there is actually an increase in endothelial cell cholesterol.
Regulation of Inflammatory Cytokines. One of the earliest gene responses to Ox-PAPC is an increase in cytokine synthesis. In contrast to inflammatory mediators lipopolysaccharide and tumor necrosis factor, induction of cytokine synthesis is sustained for at least 12 hours in response to Ox-PAPC. Furthermore, induction of cytokines by Ox-PAPC does not involve activation of NFB. Different pathways likely control the early and late cytokine responses to Ox-PAPC in endothelial cells.
Epidermal Growth Factor Receptor. One pathway regulating the early induction of cytokines involves the ability of Ox-PAPC to activate specific metalloproteinases causing the release of active receptor tyrosine kinase ligands. Activation of ADAM10 and ADAMTS4 was shown to lead to an increase in IL-8 synthesis in response to Ox-PAPC. 17 Metalloproteinase activation leads to release of active HBEGF (heparin binding epidermal growth factor), which then binds, with the epidermal growth factor receptor (EGFR) to induce IL-8 synthesis. A pathway downstream of the EGFR, involving Src, Jak and Stat activation of MCP-1 transcription has been previously identified. 102 This same pathway was involved in Ox-PAPC induced IL-8 transcription. 103 Thus the following pathway is proposed.
Ox-PAPC3ADAM*3HBEGF*3EGFR*3JAK2*3 STAT3*3IL-8
Using microarray analysis ADAM10 knockdown inhibits regulation of 30% of the Ox-PAPC response genes. 17 One mechanism of this metalloproteinase activation may involve binding of Ox-PAPC to free thiols of cysteine residues. Free thiols play an important role in activation of some metalloproteinases. PEIPC, a bioactive component of Ox-PAPC, contains an electrophilic ␣,␤ unsaturated enone group that readily forms Michael adducts with free thiols. 104 VEGFR2. An important role for VEGFR2 activation in regulating several important pathways of Ox-PAPC action in HAEC was reported. 80 Inhibition of VEGFR2 activation decreased induction of inflammatory, sterol synthesis and thrombotic genes by Ox-PAPC.
VEGFR2 activation requires Src activation, which may be a primary event or a necessary component of the activation complex. Downstream of VEGFR2, Rac1 is activated, and ultimately a NOX4 complex is formed that produces ROS. 97 Inhibition of NOX4 prevents induction of cytokines and genes of sterol regulation.
UPR Regulation of Cytokine Synthesis.
It is important to recognize that some of the Ox-PAPC effects considered protective can also be proinflammatory. For example, specific UPR proteins stimulate the inflammatory response. 96 Knockdown of UPR proteins strongly decreased basal expression and Ox-PAPC induction of IL-8, IL-6, and MCP-1. 96 Knockdown of X-box binding protein 1 (XBP1) was most effective, causing a 90% decrease in both basal and Ox-PAPC induction of cytokines. Thus UPR knockdown does not target cytokine induction by Ox-PAPC specifically but would have an overall negative effect on cytokine levels. The mechanism of this regulation is still not certain. In another study, the UPR pathway was shown to regulate IL-8 induction by HNE. 98 In this case inhibition of the UPR with overexpression of ATF6 decreased HNE induction of IL-8 but not basal levels. These studies suggest a general relationship between UPR and cytokines, but the signal transduction pathway controlling this regulation has not been identified.
Sterol Regulation of IL-8 Induction. As described above, Ox-PAPC leads to activation of SREBP. 58 SREBP activation was shown to lead to an increase in IL-8 synthesis. A sterol regulatory element was identified in the IL-8 promoter. When this element was deleted, Ox-PAPC-induced IL-8 synthesis was strongly decreased. Methyl-␤-cyclodextrin, which causes cholesterol depletion, induces IL-8, whereas cholesterol loading inhibits Ox-PAPC induction of IL-8.
In addition to the pathways discussed above, we obtained evidence that Ox-PAPC and PEIPC caused activation of PPAR alpha and Wy14643 (a PPAR alpha activator) in-creased IL-8 and MCP-1. 105, 106 However, in HAEC, knockdown of PPAR alpha only marginally decreased IL-8 induction. Taken together, these studies suggest a number of pathways regulate the early and sustained induction of cytokines by Ox-PAPC in HAEC. The current data suggest that at early times receptor tyrosine kinases may play an important role. At later times UPR and SREBP may be most important. In order to effectively inhibit Ox-PAPC induction of cytokine expression in endothelial cells, it will likely be necessary to inhibit several pathways of cytokine regulation.
Angiogenesis. Angiogenesis is a relatively late effect of Ox-PAPC and is regulated by several pathways. A recent study has shown that pyrroles, such as CEP, are recognized by a Toll-like receptor 2/Toll-like receptor 1 (TLR2/TLR1) complex and can lead to angiogenesis. 49 Many proteins containing CEP and CEP itself can activate TLR2/TLR1. Knockout of TLR2 but not CD36 or SRB1 inhibited the effect of CEP on angiogenesis. This pathway requires the presence of myeloid differentiation primary response gene (MyD88) and activation of NFB. NFB activation mediates Rac activation, followed by activation of integrin interactions with fibronectin. A similar pathway of angiogenesis occurs during development. 107 CEP3TLR2/TLR13MyD88*3NFB*3Rac*3
Integrin/FN3angiogenesis.
A number of studies demonstrated that Ox-PAPC inhibits NFB activation in response to bacterial products and does not activate NFB. 1, 2 However, CEP which is a product derived from Ox-PAPC stimulates NFB activation, demonstrating the ability of specific lipid products to mediate opposite effects on TLR signaling pathways. A separate pathway of angiogenesis was described involving NRF2. 22 In this study a 4-hour treatment of endothelial cells with Ox-PAPC increased the levels of vascular endothelial growth factor A (VEGFA), and overnight exposure led to an increase in angiogenesis. This increase in VEGFA was shown to be regulated by NRF2 activation of ATF4. An NRF2 binding element was identified in the ATF4 promoter, and an ATF4 binding site was observed in the VEGFA promoter.
Ox-PAPC-3NRF2*3ATF4 messageϩprotein3VEGFA.
Taken together, these 2 studies suggest a complex regulation of angiogenesis by several pathways. It would be valuable to examine levels of VEGFA versus activated NFB in angiogenic vessels of human lesions.
SMCs
Phenotypic Switching and Smooth Muscle Replication. Less work has been done documenting the effects of Ox-PAPC on SMCs. However, there are major proatherogenic effects on the smooth muscle phenotype. These changes include loss of smooth muscle markers, an increase in matrix synthesis and an increase in replication. In atherosclerotic lesions, SMC in the intima lose marker proteins myosin heavy chain (MHC) and ␣-actin 38 and increase matrix synthesis. 39 Treatment of SMC with Ox-PAPC or POVPC caused a strong suppression of the synthesis of mRNA for major SMC proteins ␣-actin, myosin heavy chain, and myocardin. This suppression was shown to be regulated by activation of ELK-1 108 and increased synthesis of Krueppel-like factor 4 (KLF4) (transcription that requires SP-1). 39 These 2 proteins formed a complex on the promoter that led to recruitment of HDACs inhibiting transcription of an actin. POVPC3ERK1*3ELK1*3 ␣-actin promoter 3
HDAC5
binding .
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Ox-PAPC, and 2 of its constituents, POVPC and PEIPC, also caused an increase in the synthesis of collagen VIII, fibronectin, laminin and versican. KLF4 transcript levels were strongly increased by Ox-PAPC, and knockdown of KLF4 strongly inhibited matrix synthesis in response to Ox-PAPC. Furthermore, increased binding of KLF4 to the promoter region of the collagen 8 gene was demonstrated by CHIP assay. Evidence was also presented that Sp1, a known regulator of KLF4, played a role in Ox-PAPC regulation of matrix proteins because knockdown of Sp1 inhibited KLF4mediated mRNA increases in matrix proteins. KLF4 is a molecule previously shown to regulate phenotypic switching in SMCs and levels were increased in SMC of atherosclerotic lesions. In response to Ox-PAPC, there was also an an increase in the gene expression of MCP-1 and monocyte chemotactic protein 3 (MCP-3) in these SMC. Several pathways have been demonstrated to increase SMC proliferation in response to Ox-PAPC and its components. POVPC was demonstrated to activate galactosyl transferase-2 (GALT2) to produce lactoxylceramide (LacCer). 109 LacCer then activates Nox increasing superoxide and causing activation of P21 Ras which leads to an increase in c-fos and proliferating cell nuclear antigen (PCNA).
POVPC/OxPAPC3GALT2*31LacCer3Nox*3
P21Ras*3Mapk*31cFos31PCNA.
SMC phosphorylation of cnx43 has also been shown to increase SMC replication, and Ox-PAPC was shown to increase this phosphorylation. 40, 110 Thus Ox-PL have a profound proatherogenic effect on SMC, causing phenotypic switching, cell replication, and increased production of inflammatory molecules.
Apoptosis. In human SMCs, 10 mol/L POVPC was shown to cause apoptosis as measured after 10 hours of treatment. 41 This apoptotic effect was initiated by activation of acid sphinomyelinase, resulting in the conversion of sphingomyelin to ceramide. Ceramide activates the phosphorylation of JNK and P38 MAPKs, which have been shown to activate caspase 3 and apoptosis. SMC apoptosis is an important characteristic of human lesions. A better understanding of the pathways of apoptosis could be important in stabilizing the vessel wall.
Metabolism of Ox-PL
There is considerable evidence that formation of oxidized phospholipids in atherosclerotic lesions can be initiated enzymatically. This likely occurs in tissues rather than in the blood, because levels of Ox-PL in tissues are significantly higher than levels found in plasma. 1, 2 Several enzymes have been shown to generate Ox-PL, including 12/15 LO and myeloperoxidase. Incubation of macrophages overexpressing 12/15 LO increased the formation of Ox-PL, and knockout of 12/15 LO in mice caused a 50% reduction in atherosclerosis. 10 The importance of hematopoetic cells as the source of 12/15 LO was shown in bone marrow transplantion studies. 111 An important role for myeloperoxidase in generating bioactive Ox-PL was shown by using isolated enzyme and comparing macrophages from normal and MPO-deficient patients. 9 Furthermore MPO transgenic mice had increased atherosclerosis. 112 The levels of MPO were increased in human lesions and levels of MPO in plasma were shown to predict the presence of CAD. 9 Whereas MPO-generated Ox-PL likely play an important role in the regulation of atherosclerosis, other products of MPO activity are likely also important. 9 Clinical trials of MPO or 12/15 LO inhibitors should be considered. It would be useful to know which type of macrophages are producing MPO in atherosclerosis because it might be possible to specifically target these and Figure 6 (Continued) . the vessel wall. (4) Ox-PAPC binds to the E-type prostaglandin receptor (EP2) receptor, causing deposition of connecting segment 1 (CS-1) fibronectin on the apical surface which binds monocytes. (5) Ox-PAPC activates specific a dysintegrin and metalloproteinases (ADAMs) to cause release of active heparin binding epidermal growth factor (HBEGF) and activation of epidermal growth factor receptor (EGFR), leading to interleukin (IL)-8 and monocyte chemotactic protein (MCP)-1 synthesis. (6) Ox-PAPC also activates vascular endothelial growth factor receptor 2 (VEGFR2), leading to IL-8 and MCP-1 synthesis. (7) These chemokines facilitate entry of monocytes into the vessel wall. (8) Oxidized phosphatidylcholine-containing phospholipids (Ox-PL) acting on Toll-like receptor (TLR)2, TLR4/6/cluster determinant 36 (CD36), and platelet activating factor (PAF) receptor cause some monocytes to differentiate into M1 macrophages producing chemokines. (9) Ox-PAPC causes differentiation of some macrophages into Mox, which have high levels of antioxidant enzymes and lower chemokine synthesis. (10) Ox-PAPC causes differentiation of some monocytes into dendritic cells with impaired presentation of lipid antigens. (11) Macrophages further oxidize LDL to form Ox-LDL. Ox-PC CD36 acting on CD36 in the presence of Ox-LDL causes foam cell formation. B, Advanced Lesions: (1) In the presence of Ox-PAPC and PAF-like lipids, macrophages make IL-1 beta (IL-1␤) and regulated upon activation, normal T-cell expressed, and secreted (RANTES). (2) These chemokines and a direct effect of Ox-PAPC on smooth muscle cell (SMC) cause migration and proliferation and matrix production of SMC. These SMC cover the foam cells that accumulate under the endothelium. (3) The interaction of Ox-PAPC with CD36/TLR2 and with unfolded protein response (UPR) activators and the interaction of PAF-like lipids with transmembrane protein 30A (TMEM30a) cause macrophage apoptosis. (4) Oxidized phosphatidylserine-containing phospholipids (Ox-PS)/ PC CD36 in the apopotic cell membrane bind to CD36 in macrophages, leading to macrophage uptake of the apoptotic cells. (5) Some apoptotic fragments stimulate EC to make IL-8, an angiogenic cytokine. (6) CEP activation of TLR2/TLR1 causing integrin activation and Ox-PAPC acting to increase VEGFA cause angiogenesis of adventitial vessels into the media and intima. (7) C-reactive protein (CRP) and Ox-PAPC interacting with CD36 stimulates macrophage production of metalloproteinase. This weakens the plaque and can lead to plaque rupture. (8) Ox-PAPC activation of VEGFR2 increases tissue factor synthesis in the endothelium. Ox-PAPC also causes and increases in Serpin B2 and a decrease in thrombomodulin. (9) Ox-PC CD36 acting on CD36 and PAF-like lipids acting on PAFR cause increased aggregability of platelets. (Illustration Credit: Ben Smith.) avoid problems with infections that would come from targeting macrophages in general.
There are a number of enzymes that can degrade Ox-PL and have the potential to impact atherosclerosis. There are at least 3 enzymes in plasma that can hydrolyze the sn-2 position of Ox-PL: PAF-AH, certain subtypes of phospholipase A 2 (PLA 2 ), and LCAT. 2 In cell culture hydrolysis of Ox-PAPC decreases transcriptional regulation of several genes. 113 However, the enzyme used for some of these studies was different from hydrolases found in mouse or human plasma. These studies should be repeated with more appropriate enzymes and unesterified lipid oxidation products should be synthesized and tested. In spite of the ability of PAF-AH to hydrolyze Ox-PL there is evidence that this is not a major mechanism for the regulation of PAF or PAF-like Ox-PL levels in plasma the clearance of PAF from plasma was unchanged in PAF-AH null mice and Ox-PL could competitively block this clearance. 114 A major mechanism of removal of ether-containing Ox-PL from plasma is uptake by the phospholipid transfer protein TMEM30a discussed above. 68, 114 Nonetheless, there is clear evidence that levels of PAF-AH can predict the development of CAD in humans. However, to date, PAF-AH inhibitor has not had a consistent positive effect on CAD in humans. Whereas the major effect of LCAT is transesterification of cholesterol, it can also hydrolyze Ox-PL. The in vivo effects of LCAT on Ox-PL are controversial, with some studies demonstrating increased levels of Ox-PL in the absence of LCAT and others demonstrating an inhibition of oxidation by LCAT. 2 Secretory phospholipase A 2 V, one of the most active phospholipases in the hydrolysis of lipoprotein phospholipids, promotes the inflammatory response in mice, probably by remodeling LDL to a form more rapidly taken up by scavenger receptors. The studies on PLA 2 have recently been reviewed. 115 In summary some of the PLA 2 may serve as markers of CAD, but to date an increase in the activity of these molecules in humans has not been shown to negatively impact in CAD. Thus, more specific inhibitors are needed to make firm conclusions about the effects of secretory phospholipase A 2 . A better understanding of the relative effects of PLA 2 on effects of Ox-PL in vitro and on mouse atherosclerosis will help to clarify which of these molecules should be targeted in human trials.
In addition to hydrolysis of Ox-PL as a potential protective mechanism, oxidized fatty acids containing aldehydes and epoxides such as PEIPC and POVPC can be metabolized by aldose reductase (AR) 116 ; whereas Ox-PL containing hydroperoxide groups such as 9-hydroperoxy eicosatetraenoic acid can be metabolized by glutathione peroxidases. [117] [118] [119] Somewhat surprisingly, in cultured macrophages the metabolic product of AR (1-palmitoyl-2-(5)-hydrovaleryl-snglycero-3-phosphorylcholine) was shown to increase the inflammatory response 10-to 100-fold as compared to only a 2-to 3-fold response to POVPC. 120 However, atherosclerosis was higher in AR null/apoE null mice than in mice null for apoE alone. 121 These authors carefully examined the relationship between levels of PAF-AH and levels of AR in regulating the macrophage response to POVPC. 120 They determined that inhibitors of AR were more effective than inhibitors of PAF-AH in blocking the inflammatory response in macro-phages. Thus, they conclude that in vivo the relative levels of PAF-AH and AR may be important in determining the effects of inhibitors of these 2 molecules on atherosclerosis. Taken together these studies point out important considerations in targeting enzymes that metabolize Ox-PL. Two other major enzymes involved in the metabolism of Ox-PL have glutathione peroxidase activity and are able to reduce phospholipid hydroperoxides to hydroxides: glutathione peroxidase 4 and peroxiredoxin 6. Peroxiredoxin 6 has a PLA 2 as well as a peroxidase activity. 117 The ability of both of these enzymes to use Ox-PL as substrates has been verified. 118 Overexpression of glutathione peroxidase 4 in apoE null mice was shown to reduce lesion formation and to decrease the complexity of more advanced lesions. 119 The ability of peroxiredoxin 6 to reduce the size of atherosclerotic lesions has also been reported, however, the effect is very dependent on the strain tested. Overall, because of their effects on atherosclerosis in mice, the molecules that metabolize Ox-PL have promise as therapeutic targets.
Conclusions
The preponderance of studies demonstrates that Ox-PL is present in human and mouse atherosclerotic lesions and contribute to lesion formation. The amount of Ox-PL in lesions is sufficient to cause proatherogenic effects on cells in culture, and some of the pathways identified in vitro as regulated by Ox-PL are also activated in human or mouse lesions and affect atherosclerosis. Levels of Ox-PL and of MPO in blood of patients predict development of CAD. Furthermore injection of F(ab) fragments of antibodies to Ox-PL inhibit the development of atherosclerosis in mice. 122 These studies suggest that Ox-PL can be both a marker and therapeutic target for CAD. Thus, the studies discussed here and in earlier reviews, identify a number of novel therapeutic targets (receptors and enzymes), signaling pathways, and Ox-PL-lowering approaches to confront the atherogenic effects of Ox-PL.
Based on studies in mice, one of the most effective strategies might be to alter levels of Ox-PL with antibodies to these lipids. These results suggest that Ox-PL vaccination would potentially protect against atherosclerosis. HDL has been shown to be able to bind Ox-PL but its cholesterol transport function is compromised. Another strategy is using synthetic molecules that retain the Ox-PL binding function of HDL without altering the protective effects of HDL. D4F, an HDL mimetic peptide, is an example of this approach. Another possibility is to alter synthesis and/ or degradation of Ox-PL. Studies in mice and in humans suggest that inhibitors of MPO and 12/15 LO, both enzymes which increase Ox-PL levels, may have a therapeutic potential. Another strategy is to increase enzymes that degrade Ox-PL. However, recent studies suggest that it will be important to determine the activity of the lipids after treatment with various PLA 2 enzymes and reductases. In addition, the relative importance of the individual enzymes in lowering levels of active Ox-PL and atherosclerosis need to be clarified.
In vitro and in vivo studies over the past 5 years have identified receptors and signaling pathways that could be targets to inhibit the proatherogenic effects of Ox-PL ( Figure  6 ). These studies have made it clear that multiple receptors and signaling pathways can regulate one response such as angiogenesis. Therefore it may be necessary to target more than one receptor or signaling pathway. A striking finding of the recent studies is the importance of receptor complexes in many of the actions of Ox-PL. Several of these complexes contain TLRs and CD36. Studies in mice demonstrate that targeting of TLR2 and 4 reduces some aspects of atherosclerosis but some effects are limited to early stages. Because TLRs also protect against bacterial infection, it will be important to target inhibitors to atherosclerotic lesions. The importance of covalent binding of Ox-PL to proteins has emerged as an important aspect of their mechanism of action. It may be possible to inhibit covalent binding with compounds such as n-acetyl cysteine which can covalently bind Ox-PL and reduce many proatherogenic effects in vitro. In addition, it is apparent that Ox-PL alter the lipid raft fraction and these changes in lipid rafts may contribute to the mechanisms of Ox-PL action. A better understanding of the mechanisms by which Ox-PL alter membrane composition will define important targets in this pathway. In general, in choosing receptors and pathways to target, it will be important to gain more understanding of the stages of atherosclerosis regulated by these receptors and pathways. Studies in mice at both early and late stages and studies of signaling pathways in human lesions will be very helpful in this process.
In using inhibitors to target the proatherogenic effects of Ox-PL it is important to recognize that Ox-PL can also have protective effects. For example, PEIPC at low concentrations protects endothelial barrier function. Ox-PAPC increases the levels of antioxidant enzymes, binds to complement factor H to inhibit inflammation and can under some circumstances promotes cell survival by inducing UPR and related pathways. However, some aspects of the UPR, such as effects on inflammation and apoptosis, can be proatherogenic making it important to gain a better understanding of the regulation of the major UPR responses in atherosclerosis. In general, at least some of the protective effects of Ox-PL are mediated by different signaling pathways from the atherogenic effects. It will be important to determine which Ox-PL lipid, which receptors and which signaling pathways promote atherogenesis and which are protective. With knowledge of the protective and the proatherogenic effects of Ox-PL in different vascular cell types, it should be possible to design experiments to test the effect of inhibition of specific pathways in specific cell types on the development of atherosclerosis in mice.
It also may be possible to identify individuals most likely to benefit from Ox-PL inhibition. Using endothelial cells from 150 heart transplant donors we have determined that there are major differences in the effects of Ox-PAPC in different individuals. 21, 99 We have identified several genes that control aspects of this sensitivity. We also have data suggesting differences in sensitivity in macrophages from different individuals (A.J.L., unpublished observation). From these studies it may be possible to identify polymorphisms that effect susceptibility to Ox-PL and would indicate individuals who might most benefit from reduction in Ox-PL levels or signaling.
